Summary
Unmodified vinblastine (VLB) targeted through one of the antigen combining sites of the hybrid-hybrid 28.19.8 monoclonal is potentially more effective in suppressing the growth of established MAWI tumour xenografts implanted on nude mice than free VLB in the absence of the targeting agent, presumably due to an increased local drug concentration. Our efficacy results in this study suggest that drug, specifically removed from the circulation by hybrid-hybrid antibody previously located to the tumour mass, can be made available in a pharmacologically active from. Histological analysis of the treated tumours revealed dramatic changes in the tumour organisation with only a few surviving tumour cells with altered morphology.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baldwin RW, Byers VS (eds) (1985) In: Monoclonal antibodies for cancer detection and therapy. Academic Press
Bernstein ID, Tam MR, Nowinski RC (1980) Mouse leukemia:therapy with monoclonal antibodies against a thymus differentiation antigen. Science 207:68
Capone PM, Papsidero LD, Croghan GA, Ming Chu T (1983) Experimental tumoricidal effects of monoclonal antibody against solid breast tumours. Proc Natl Acad Sci USA 80:7328
Corvalan JRF, Axton CA, Brandon DR, Smith W, Woodhouse CS (1984) Classification of anti-CEA monoclonal antibodies. Protides of the Biol Fluids 31:921
Corvalan JRF, Smith W (1987) Construction and characterisation of a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids. Cancer Immunol Immunother 24:127–132
Corvalan JRF, Smith W, Gore VA, Brandon DR (1987) Specific in vitro and in vivo drug localisation to tumour cells using a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids. Cancer Immunol Immunother 24:133–137
Couderc J, Kazatchkine MD, Ventura M, Thien Duc H, Maillet F, Thobie N, Liacopoulos P (1985) Activation of the human classical complement pathway by a mouse monoclonal hybrid IgG1–2a monovalent anti-TNP antibody bound to TNP-conjugated cells. J Immunol 134:486
Kanellos J, Pietersz GA, McKenzie IFC (1985) Studies of methotrexate-monoclonal antibody conjugates for immunotherapy. J Natl Cancer Inst 75:319
Lewis JCM, Smith PA, Keep PA, Boxer GM (1983) A comparison of the content and immunohistochemical patterns of CEA-like activity in human colorectal tumours and nude mouse xenografts. Exp Pathol 24:227
Moller G (ed) (1982) Antibody carriers of drugs and toxins in tumour therapy. Immunol Rev 62
Rowland GF, Axton CA, Baldwin RW, Brown JP, Corvalan JRF, Embleton MJ, Gore VA, Hellstrom I, Hellstrom KE, Jacobs E, Marsden CH, Pimm MV, Simmonds RG, Smith W (1985) Antitumour properties of vindesine-monoclonal antibody conjugates. Cancer Immunol Immunother 19:1
Rowland GF, Simmonds RG, Gore VA, Marsden CH, Smith W (1986) Drug localisation and growth inhibition studies of vindesine-monoclonal anti-CEA conjugates in a human tumour xenograft. Cancer Immunol Immunother 21:183
Simmonds RG, Smith W, Corvalan JRF (1984) Affinity purification of anti-CEA antibody. Protides of the Biol Fluids 31:917
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Corvalan, J.R.F., Smith, W., Gore, V.A. et al. Increased therapeutic effect of vinca alkaloids targeted to tumour by a hybrid-hybrid monoclonal antibody. Cancer Immunol Immunother 24, 138–143 (1987). https://doi.org/10.1007/BF00205591
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00205591